Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
The price of Lexeo Therapeutics Inc (NASDAQ: LXEO) closed at $9.43 in the last session, down -4.84% from day before closing price of $9.91. In other words, the price has decreased by -$4.84 from its previous closing price. On the day, 1.28 million shares were traded. LXEO stock price reached its highest trading level at $10.0 during the session, while it also had its lowest trading level at $9.375.
Ratios:
We take a closer look at LXEO’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 4.43 and its Current Ratio is at 4.43. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.05.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Guggenheim on October 15, 2025, initiated with a Buy rating and assigned the stock a target price of $30.
On July 31, 2025, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $20.
On June 13, 2024, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $28.Robert W. Baird initiated its Outperform rating on June 13, 2024, with a $28 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Oct 17 ’25 when See Tai Sandi sold 3,888 shares for $8.94 per share. The transaction valued at 34,767 led to the insider holds 65,862 shares of the business.
Robertson Jenny sold 3,526 shares of LXEO for $31,530 on Oct 17 ’25. The Chief Legal Officer now owns 68,930 shares after completing the transaction at $8.94 per share. On Oct 17 ’25, another insider, Otero Jose Manuel, who serves as the Chief Technical Officer of the company, sold 2,115 shares for $8.94 each. As a result, the insider received 18,913 and left with 64,197 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LXEO now has a Market Capitalization of 678676800 and an Enterprise Value of 385215360.
Stock Price History:
The Beta on a monthly basis for LXEO is 1.92, which has changed by 0.1891551 over the last 52 weeks, in comparison to a change of 0.19088471 over the same period for the S&P500. Over the past 52 weeks, LXEO has reached a high of $11.72, while it has fallen to a 52-week low of $1.45. The 50-Day Moving Average of the stock is 39.37%, while the 200-Day Moving Average is calculated to be 106.33%.
Shares Statistics:
According to the various share statistics, LXEO traded on average about 857.72K shares per day over the past 3-months and 1419320 shares per day over the past 10 days. A total of 54.00M shares are outstanding, with a floating share count of 42.55M. Insiders hold about 21.20% of the company’s shares, while institutions hold 74.52% stake in the company. Shares short for LXEO as of 1760486400 were 7315216 with a Short Ratio of 8.53, compared to 1757894400 on 5891889. Therefore, it implies a Short% of Shares Outstanding of 7315216 and a Short% of Float of 14.850000999999999.
Earnings Estimates
. The current assessment of Lexeo Therapeutics Inc (LXEO) involves the perspectives of 6.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$0.42, with high estimates of -$0.28 and low estimates of -$0.6.
Analysts are recommending an EPS of between -$1.99 and -$3.03 for the fiscal current year, implying an average EPS of -$2.45. EPS for the following year is -$1.8, with 6.0 analysts recommending between -$1.12 and -$2.54.
